Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 – December 1, 2022 in New York.
Piper Sandler 34th Annual Healthcare Conference
Date: Tuesday, November 29, 2022
Time: 4:00 p.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: In-person fireside chat and 1-on-1 meetings
https://event.webcasts.com/starthere.jsp?ei=1584856&tp_key=e9a7246381
A replay of the presentation will be available in the Investors/Media section of Infinity's website at www.infi.com for 90 days following the event.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005211/en/
Contacts
Investor Relations:
Luke Heagle
Real Chemistry
lheagle@realchemistry.com
